Clinical Hemp OilsTM

Extraordinary hemp therapeutics reuniting science and Nature.

Our mission is serving your patients’ health.

Cannacea offers practitioners scientific hemp oil supplements with certified clinical constituency and purity. Researched and developed over two decades, Cannacea crafts the ultimate phytocannabinoid therapeutics. Today, Cannacea excels for your patients’ health.

Partnered with the Realm of Caring Foundationpioneers of CBD awareness, research, and civil rights – to support you and your patients.


The Endocannabinoid System (ECS) is involved in multiple physiological and psychological functions of clinical interest. Notably, the ECS and the functions it regulates can be variably modulated by phytocannabinoids. [1-3]

Clinical studies indicate the intake of phytocannabinoids can provide health benefits for some people [4-8, 14, 15, 21, 22]. The efficacy and safety of phytocannabinoid intake appears to improve when delivered in a full spectrum complex instead of in isolation [see subsection].

Clinical applications demand endocannabinoid supplements be science-driven phytocannabinoid preparations with exceptional certified potencies and purity. [4]

CANNACEA – Clinical Phytochemistry and Purity.

  • Formulations based on advanced research, analytics, and development.
  • Rigorously-validated Certified Organic ingredients, processing, and manufacture in a cGMP Certified facility (BRCGS).

Life Intelligence.TM

Click on the section headings below to discover the science and special qualities of Cannacea hemp oils.

Or directly action one of the following:


Endocannabinoid System

The Endocannabinoid System (ECS) is a vast biological system, expressed throughout the vertebrate central nervous system, peripheral nervous system, and peripheral organs. The ECS influences the activity of multiple receptor types and neurotransmitters involved in a wide variety of physiological and psychological functions. [1, 3]

Decades of scientific research reveal the ECS plays a major homeostatic role in:

  • Neurological function
  • Sleep
  • Inflammation
  • Sensation
  • Pain
  • Appetite
  • Digestion
  • Immune function
  • Psychological function
  • Cellular growth & proliferation
  • Metabolism
  • Learning
  • Memory
  • and others…
    [1, 3]
Some organs and systems with CB Receptors [1]

The ECS is a complex interplay between:

  1. Endogenous neurotransmitter “endocannabinoids”, mainly N-arachidonoyl ethanolamide (AEA, “anandamide”) and 2-arachidonoyl glycerol (2-AG). [1, 3]

  2. Two G-protein-coupled receptors (GPCRs), named Cannabinoid Receptor 1 (CB1) and 2 (CB2), found across the body, as well as various receptor types like 5-HT, GABA, Glutamate, and others, TRP ion channels, plus CB receptor heterodimers with Opioid, Dopamine, and other major receptor types – all modulated by the endocannabinoids. [1-3]

  3. Endogenous enzymes that synthesize and degrade the endocannabinoids (FAAH, MAGL,…). [1, 3]

Additional science and history of the ECS can be discovered here in the Cannacea-verse.

Phytocannabinoid Supplementation

The phytocannabinoids produced by cannabis have been proven to supplement the endocannabinoids through their interaction with the ECS [12]. The phytocannabinoids demonstrate:

  • Unique affinities and activities at CB1 and CB2 receptors, at TRP ion channels, and at various receptor types: 5-HT, GABA, Glutamate, Opioid, Dopamine, and others. [1-3, 12]

  • Unique abilities to inhibit the reuptake of the endocannabinoids and the enzymes that degrade the endocannabinoids. [13]

Click these prevalent phytocannabinoids in Cannacea hemp oils to uncover added information and structure/function effects for each:

“The physician assists Nature.”
– Galen

Original image by Bernard Gagnon (Creative Commons)

Growing peer-reviewed scientific research from human, animal, and in vitro studies evidences significant health benefits from supplementing the ECS with phytocannabinoids. [4-8, 14, 15, 21, 22]

While added randomized, controlled clinical studies are needed to give a more detailed picture of the health benefits provided by phytocannabinoid supplementation, there is already ample scientific evidence to support this reality. For example, these 3 prospective studies:

  • One prospective study of 901 subjects over age 65 undergoing phytocannabinoid therapy resulted in 93.7% of respondents reporting improvement in their wellness, with 41.9% reporting significant improvement. For example, prior to treatment 66.8% of respondents reported high pain intensity (“8 – 10” on scale of 10), while after 6 months of treatment only 7.6% reported high pain intensity. [7]

  • One 8-week prospective study gave oral CBD-rich full spectrum hemp extract to 97 subjects aged 39 – 70 suffering from chronic pain and taking opioids for at least 1 year. Nearly all subjects (94%) took 30 mgCBD/day. 94% of subjects reported improved quality of life and 53% significantly reduced or eliminated opioid use. Significant reductions in pain intensity and interference were reported, along with significant improvements in sleep quality. [14]

  • One prospective study analyzed 2,431 subjects experiencing at least one of the six most common Palliative Care issues, who were vaporizing cannabis varieties across a wide range of CBD:THC ratios. On an 11-point scale of issue severity (0 – 10), there was at least a 3-point improvement from pre-use to post-use severity for the following percentage of subjects experiencing such issues:
    • PTSD-related flashbacks: 78%
    • Anorexia: 77%
    • Insomnia: 71%
    • Anxiety: 66%
    • Depression: 61%
    • Neuropathic pain: 42%

Full Spectrum Synergy

Superior therapeutic efficacy of whole plant extracts over single compounds is frequently reported in the scientific literature. [16-18]

Studies also demonstrate a broader range of efficacies and reduced adverse effects if using cannabis preparations containing multiple phytocannabinoids and other natural compounds produced in cannabis versus only using isolated or purified cannabinoids. [13, 19-24]

Such synergistic effects of a natural complete cannabis phytochemical profile are evidenced by the research examples below, and have been famously named the “Entourage Effect”. [19]

The mature Cannabis flower – a phytochemical powerhouse.

Multiple peer-reviewed scientific studies confirm the therapeutic superiority of full spectrum hemp oil phytochemical profiles over purified CBD or CBD isolates:

  • A meta-analysis with 670 subjects showed intakes of full spectrum CBD-rich preparations resulted in significantly increased benefits compared with intakes of isolated or purified CBD, also reducing CBD intake by 75%, reducing mild adverse effect rates by 50%, and reducing severe adverse effects rates by over 65%. [21]

  • One study with 10 pediatric subjects also showed the use of full spectrum CBD-rich preparations resulted in significantly increased benefits and reduction in adverse side effects compared with using isolated or purified CBD. [22]

  • One study in mice showed CBD isolate oral intake was limited by a “bell-shaped” intake response for anti-nociception and anti-inflammation. In contrast, oral intake of full spectrum CBD-rich preparation did not have such dose limitation, and demonstrated continuously increasing effects upon increasing intakes that required ~2.5x less CBD for equivalent therapeutic effect (see Figure A, below). [23]
Figure A: Comparing therapeutic effect of oral intakes by mice of CBD isolate vs. CBD in a full spectrum. (a) & (b) – Prevention of zymosan-induced swelling of hind paw. (c) & (d) – Anti-nociception in a von Frey nociceptive filament assay.
Adapted from Gallily et al. (2015). [23]
  • One human study found a panel of 30 subjects was consistently experiencing specific subjective effects in relation to specific phytocannabinoid and phytoterpene chemotypes they were using. [24]

  • Several human studies demonstrate that CBD suppresses various side effects of THC when the two are taken together, particularly when more CBD than THC is taken. [25-27]

  • One in vitro study compared phytocannabinoid isolates to full spectrum preparations having those same phytocannabinoids at 40% – 70% with the remainder a complex mixture of other phytocannabinoids and non-cannabinoid natural compounds.  Various assays showed the full spectrum preparations almost always displayed significantly higher potency and efficacy in inhibiting the enzymes responsible for degrading the main endocannabinoids (AEA and 2-AG), and in inhibiting the cellular reuptake of AEA. [13]

A holistic scientific approach to plant therapy.

Complete harnessing of hemp’s unique powers.

Genuine Full Spectrum Hemp Oils.








  1. Aizpurua-Olaizola, O et al. (2017). Targeting the endocannabinoid system: future therapeutic strategies. Drug Discovery Today 22(1): 105-110.
  2. Morales, P, Reggio, PH (2017). An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis and Cannabinoid Research 2(1): 265-273.
  3. Stasiulewicz, A et al. (2020). A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences 21(8): 2778.
  4. VanDolah, HJ et al. (2019). Clinician’s Guide to Cannabidiol and Hemp Oils. Mayo Clinic Proceedings 94(9): 1840-1851.
  5. Sholler, DJ et al. (2020). Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Current Addiction Reports 7(3): 405-412.
  6. Khan, R et al. (2020). The therapeutic role of Cannabidiol in mental health: a systematic review. Journal of Cannabis Research 2:2.
  7. Abuhasira, R et al. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine 49: 44-50.
  8. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
  9. Russo, EB, Marcu, J (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in Pharmacology 80: 67-134.
  10. Orsavova, J et al. (2015). Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. International Journal of Molecular Sciences 16(6): 12871-12890.
  11. Krut, LH, Bronte-Stewart, B (1964). The fatty acids of human depot fat. Journal of Lipid Research 5(3): 343-351.
  12. Turner, SE et al. (2017). Molecular Pharmacology of Phytocannabinoids. In Kinghorn, AD; Falk, H; Gibbons, S; Kobayashi, J (eds.). Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. Progress in the Chemistry of Organic Natural Products 103. Springer International Publishing: 61–101.
  13. De Petrocellis, L et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology 163(7): 1479-1494.
  14. Capano, A et al. (2020). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine 132(1): 56-61.
  15. Casarett, DJ et al. (2019). Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of Palliative Medicine 22(10): 1180-1184.
  16. Wagner, H, Ulrich-Merzenich, G (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine 16(2-3): 97-110.
  17. Rasoanaivo, P et al. (2011). Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malaria Journal 10(Suppl.1): 1-12.
  18. Yuan, H et al. (2017). How Can Synergism of Traditional Medicines Benefit from Network Pharmacology? Molecules 22(7): 1135-1153.
  19. McPartland, JM, Russo, EB (2001). Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? Journal of Cannabis Therapeutics 1(3-4): 103-132.
  20. Russo, E (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163(7): 1344-1364.
  21. Pamplona, FA et al. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology 9: 759.
  22. Zafar, R et al. (2021). Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatrics Open 5: e001234.
  23. Gallily, R et al. (2015). Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology and Pharmacy 6: 75-78.
  24. Lewis, MA et al. (2018). Pharmacological Foundations of Cannabis Chemovars. Planta Medica 84(04): 225-233.
  25. Karniol, IG et al. (1974). Cannabidiol interferes with the effects of delta 9- tetrahydrocannabinol in man. European Journal of Pharmacology 28(1): 172– 177.
  26. Zuardi, AW et al. (1982). Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology (Berl) 76(3): 245–250.
  27. Bhattacharyya, S et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3): 764-774.
  28. Izzo, L et al. (2020). Analysis of Phenolic Compounds in Commercial Cannabis sativa L. Inflorescences Using UHPLC-Q-Orbitrap HRMS. Molecules 25(3): 631.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.